Dental products company Dentsply Sirona (NASDAQ:XRAY) announced better-than-expected revenue in Q2 CY2026, but sales fell by 4.1% year on year to $898 million. On the other hand, the company’s full-year revenue guidance of $3.55 billion at the midpoint came in 1% below analysts’ estimates. Its non-GAAP profit of $0.52 per share was 50.1% above analysts’ consensus estimates.
Is now the time to buy XRAY? Find out in our full research report (it’s free for active Edge members).
Dentsply Sirona (XRAY) Q2 CY2026 Highlights:
- Revenue: $898 million vs analyst estimates of $892.6 million (4.1% year-on-year decline, 0.6% beat)
- Adjusted EPS: $0.52 vs analyst estimates of $0.35 (50.1% beat)
- Adjusted EBITDA: $190 million vs analyst estimates of $146.8 million (21.2% margin, 29.4% beat)
- The company reconfirmed its revenue guidance for the full year of $3.55 billion at the midpoint
- Management reiterated its full-year Adjusted EPS guidance of $1.45 at the midpoint
- Operating Margin: 9.1%, up from -13.7% in the same quarter last year
- Market Capitalization: $2.64 billion
StockStory’s Take
Dentsply Sirona’s second quarter results were met with a negative market reaction, as shares declined following revenue and non-GAAP earnings that exceeded Wall Street expectations. Management attributed the year-on-year revenue decline primarily to lower sales volumes in key product segments and regions, especially in the Americas and EMEA, and highlighted ongoing challenges in capital equipment demand and inventory reduction by distributor partners. CEO Daniel Scavilla described the company’s current phase as a “turnaround,” noting that while some parts of the business are stabilizing, improvement remains uneven across segments and geographies. The impact of tariff refunds also influenced quarterly profitability, but underlying operational momentum was mixed.
Looking ahead, Dentsply Sirona’s guidance is shaped by its ongoing return-to-growth initiatives and expectations of improvement from recent investments in salesforce expansion, clinical education, and digital product adoption. Management expects these measures to yield more visible results in the fourth quarter and beyond, with particular emphasis on expanded dealer partnerships and enhanced commercial capabilities. CEO Daniel Scavilla stated, “We are making progress, but this is still a turnaround,” while highlighting that the most significant benefits from strategic changes and new hires are likely to materialize next year rather than in the immediate term. The company remains focused on strengthening its financial foundation and executing operational changes to support long-term growth.
Key Insights from Management’s Remarks
Management attributed the quarter’s performance to lower volumes in the Americas, inventory reductions by distributors in Europe, and mixed trends across product lines and geographies. Tariff refunds provided a one-time profit benefit, while ongoing investments in education and commercial capabilities remain a central focus.
- Tariff refund impact: Earnings in the quarter were positively affected by a $44 million tariff refund, which contributed $0.17 per share in adjusted EPS, but management emphasized this was a non-recurring benefit rather than a reflection of underlying business strength.
- Segment and regional variability: The CTS (Consumables, Technology & Services) segment saw mixed results, with flat equipment sales offset by weaker CADCAM performance in the Americas and strong momentum in Asia-Pacific. EMEA demand softened due to capital spending delays linked to Middle East tensions.
- Inventory dynamics: European distributors reduced inventory levels, which lowered reported sales but was not attributed to weakened end-market demand. Management believes this adjustment will not have a long-term impact on customer consumption trends.
- Commercial and salesforce investments: Dentsply Sirona continued to invest in salesforce expansion, particularly in the U.S., and in clinical education initiatives globally. Recent dealer partnerships in North America and Canada are expected to gradually improve market reach and sales productivity.
- Wellspect Healthcare outperformance: The Wellspect Healthcare division delivered robust revenue growth, driven by new product launches and expansion in key markets. Management cited Wellspect as an example of successful execution and intends to replicate similar strategies across other segments.
Drivers of Future Performance
Management’s outlook for the remainder of the year centers on the pace of commercial execution, the timing of operational improvements, and the impact of continued investments in salesforce training and digital platform adoption.
- Commercial expansion effects delayed: The full benefit from expanded dealer networks and salesforce training is expected to become more apparent in late 2026 and 2027 as new representatives ramp up productivity and pipeline development matures. Management acknowledged the lag between hiring and revenue generation, especially in capital equipment sales.
- Macro and geopolitical headwinds: Uncertainty in Europe, driven by Middle East conflict and broader macroeconomic factors, continues to delay capital equipment purchases and introduce freight cost volatility. Management is monitoring these risks but has not revised investment plans unless external pressures intensify.
- Innovation and digital adoption: Ongoing investments in digital dentistry solutions, such as DS Core, and new product launches in Wellspect and EDS (Endodontic, Restorative & Preventive) are expected to gradually support revenue growth. However, the impact of these initiatives will be contingent on regulatory approvals and the speed of customer adoption.
Catalysts in Upcoming Quarters
Looking forward, our analyst team will watch (1) the pace at which new dealer partnerships and salesforce investments translate into higher sales, particularly in the U.S. and APAC, (2) stabilization of inventory levels at European distributors and any rebound in capital equipment demand, and (3) the progress of digital platform adoption and regulatory milestones for new product launches. Execution in these areas will be critical to Dentsply Sirona’s turnaround trajectory.
Dentsply Sirona currently trades at $12.20, down from $13.17 just before the earnings. In the wake of this quarter, is it a buy or sell? Find out in our full research report (it’s free).
Our Favorite Stocks Right Now
ONE MORE THING: Top 6 Stocks for This Week. This market is separating quality stocks from expensive ones fast. AI is taking down whole sectors with no warning. In a rotation this fast, you need more than a list of good companies.
Our AI system flagged Palantir before it ran 1,662% between October 2022 and February 2026. AppLovin before it ran 753% between February 2024 and February 2026. Nvidia before it ran 1,178% between January 2023 and February 2026. Each week it produces 6 new names that pass the same tests. Get Our Top 6 Stocks for Free HERE.
Stocks that have made our list include now familiar names such as Nvidia (+1,460% between June 2020 and June 2025) as well as under-the-radar businesses like the once-micro-cap company Kadant (+214% between June 2020 and June 2025). Find your next big winner with StockStory today.